Literature DB >> 3361574

Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.

G J Atwell1, C D Bos, B C Baguley, W A Denny.   

Abstract

A series of isomeric phenylquinoline-8-carboxamides have been synthesized and evaluated as antitumor agents. This configuration is close to the minimum chromophore required for intercalative binding, since the binding mode of the compounds is dependent on the presence and position of the phenyl ring. If the ring is appended at the 4- or 5-position, it cannot lie within the DNA-intercalation site, and the compounds do not intercalate as shown by both unwinding and helix extension assays. In contrast, the 2-, 3-, and 6-phenyl isomers (where the phenyl ring lies coplanar with the quinoline and in the intercalation site) bind by intercalation. Only those isomers that intercalate show in vivo antitumor activity, with the 2-phenyl derivative in particular possessing broad-spectrum activity in both leukemia and solid-tumor assays.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361574     DOI: 10.1021/jm00400a029

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Molecular modeling study of intercalation complexes of tricyclic carboxamides with d(CCGGCGCCGG)₂ and d(CGCGAATTCGCG)₂.

Authors:  Athanasia Varvaresou; Kriton Iakovou
Journal:  J Mol Model       Date:  2010-12-14       Impact factor: 1.810

2.  Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics.

Authors:  Wei Shi; Robert S Coleman; Todd L Lowary
Journal:  Org Biomol Chem       Date:  2009-07-17       Impact factor: 3.876

3.  N-Isopropyl-6-methyl-2-phenyl-quinoline-3-carboxamide.

Authors:  Saida Benzerka; Abdelmalek Bouraiou; Sofiane Bouacida; Thierry Roisnel; Ali Belfaitah
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.